The potential reassessment of cannabinoids, particularly at the federal level, is generating considerable excitement within the market. A shift away from Schedule I status, often regarded as outdated and hindering progress, could unlock significant avenues for companies. Reduced regulatory impediments, alongside greater access to banking and invest